Keyphrases
Encephalopathy
100%
Single-center Experience
100%
Immune Checkpoint Inhibitor Therapy
100%
Central Nervous System Malignancies
57%
Immune Checkpoint Inhibitors
57%
Central Nervous System Tumors
28%
Nivolumab
28%
Neurotoxicity
14%
Tertiary Care Hospital
14%
Patient Characteristics
14%
Clinical Features
14%
Demographic Characteristics
14%
Treatment Cycle
14%
Neurologist
14%
Adult Patients
14%
Collaborative Care
14%
Brain Imaging
14%
Standard of Care
14%
Contrast-enhancing Lesions
14%
Electroencephalogram
14%
Ipilimumab
14%
Central Nervous System Lesions
14%
Pembrolizumab
14%
Timely Administration
14%
Medicine and Dentistry
Brain Disease
100%
Immune Checkpoint Inhibitor
100%
Central Nervous System
71%
Cancer
57%
Central Nervous System Tumor
28%
Nivolumab
28%
Clinical Feature
14%
Tertiary Care
14%
Neurotoxicity
14%
Brain Imaging
14%
Electroencephalogram
14%
Ipilimumab
14%
Pembrolizumab
14%